Benefits to being a partner in the PRECEDE Consortium
– PRECEDE enables Breakthrough Genomics to collaborate with some the world’s leading pancreatic cancer scientists, practicioners, and high risk centers
– PRECEDE is the largest longitudinal study of its kind with more than 7000 patients already enrolled and over 54 participating insitutions
– PRECEDE has an ambitious goal that we are proud to work toward: improving the 5-year survival rate by nearly 400% within 10 years
Early Detection is the key to reaching this goal and we are confident that the
BT-Reveal Early Pancreatic Cancer Test is up to the task
